Oppenheimer analyst Leah R. Cann maintained a Hold rating on Crispr Therapeutics AG (NASDAQ: CRSP) today. The company’s shares opened today at $55.31.
Cann observed:
“The diabetes field is a large and important market for therapeutic development and this collaboration between CRISPR Therapeutics and ViaCyte has the promise of leading to additional clinical pipeline programs for CRISPR Therapeutics in a new disease setting. However, based on it currently being in the discovery phase, we believe it is too early to adjust our outlook. Therefore, our outlook and estimates for revenue remain unchanged at this time.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 21.0% and a 54.7% success rate. Cann covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, Miragen Therapeutics Inc, and CytomX Therapeutics Inc.
Crispr Therapeutics AG has an analyst consensus of Moderate Buy, with a price target consensus of $72.50.
See today’s analyst top recommended stocks >>
Based on Crispr Therapeutics AG’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $38.38 million. In comparison, last year the company had a GAAP net loss of $22.32 million.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CRISPR Therapeutics AG engages in the development and commercializtion of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, and Shaun Patrick Foy in 2014 and is headquartered in Zug, Switzerland.
